Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3

Åsa Alsiö, Karolina Rembeck, Galia Askarieh, Peer Brehm Christensen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Court Pedersen, Kristine Mørch, Bart L Haagmans, Salmir Nasic, Johan Westin, Kristoffer Hellstrand, Gunnar Norkrans, Martin Lagging

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.
OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind7
Udgave nummer5
Sider (fra-til)e37521
ISSN1932-6203
DOI
StatusUdgivet - 2012

Fingeraftryk

chronic hepatitis C
Hepatitis C virus
Ribavirin
Chronic Hepatitis C
Virus Diseases
interferons
Viruses
Hepacivirus
Interferons
body mass index
bioavailability
Body Mass Index
obesity
therapeutics
genotype
infection
Biological Availability

Citer dette

Alsiö, Åsa ; Rembeck, Karolina ; Askarieh, Galia ; Christensen, Peer Brehm ; Färkkilä, Martti ; Langeland, Nina ; Buhl, Mads Rauning ; Pedersen, Court ; Mørch, Kristine ; Haagmans, Bart L ; Nasic, Salmir ; Westin, Johan ; Hellstrand, Kristoffer ; Norkrans, Gunnar ; Lagging, Martin. / Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. I: P L o S One. 2012 ; Bind 7, Nr. 5. s. e37521.
@article{6c34b02b50cf4a7bb30a731a905429ba,
title = "Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3",
abstract = "Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.",
author = "{\AA}sa Alsi{\"o} and Karolina Rembeck and Galia Askarieh and Christensen, {Peer Brehm} and Martti F{\"a}rkkil{\"a} and Nina Langeland and Buhl, {Mads Rauning} and Court Pedersen and Kristine M{\o}rch and Haagmans, {Bart L} and Salmir Nasic and Johan Westin and Kristoffer Hellstrand and Gunnar Norkrans and Martin Lagging",
year = "2012",
doi = "10.1371/journal.pone.0037521",
language = "English",
volume = "7",
pages = "e37521",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

Alsiö, Å, Rembeck, K, Askarieh, G, Christensen, PB, Färkkilä, M, Langeland, N, Buhl, MR, Pedersen, C, Mørch, K, Haagmans, BL, Nasic, S, Westin, J, Hellstrand, K, Norkrans, G & Lagging, M 2012, 'Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3', P L o S One, bind 7, nr. 5, s. e37521. https://doi.org/10.1371/journal.pone.0037521

Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. / Alsiö, Åsa; Rembeck, Karolina; Askarieh, Galia; Christensen, Peer Brehm; Färkkilä, Martti; Langeland, Nina; Buhl, Mads Rauning; Pedersen, Court; Mørch, Kristine; Haagmans, Bart L; Nasic, Salmir; Westin, Johan; Hellstrand, Kristoffer; Norkrans, Gunnar; Lagging, Martin.

I: P L o S One, Bind 7, Nr. 5, 2012, s. e37521.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3

AU - Alsiö, Åsa

AU - Rembeck, Karolina

AU - Askarieh, Galia

AU - Christensen, Peer Brehm

AU - Färkkilä, Martti

AU - Langeland, Nina

AU - Buhl, Mads Rauning

AU - Pedersen, Court

AU - Mørch, Kristine

AU - Haagmans, Bart L

AU - Nasic, Salmir

AU - Westin, Johan

AU - Hellstrand, Kristoffer

AU - Norkrans, Gunnar

AU - Lagging, Martin

PY - 2012

Y1 - 2012

N2 - Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.

AB - Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.

U2 - 10.1371/journal.pone.0037521

DO - 10.1371/journal.pone.0037521

M3 - Journal article

VL - 7

SP - e37521

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 5

ER -